Pacific Biosciences of California, Inc. PACB
Set alert
At close · Oct 30
After hours · Oct 30, 7:34 PM ET
- YTD
- +39.30%
- 1 year
- +34.28%
- Open
- 2.75
- Prev close
- 2.90
- Mkt cap
- 809.71M
- Vol
- 13.74M
- Avg vol
- 12.02M
- EPS
- -0.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.41
- High
- 2.82
- Forward P/E
- -2.84
- Beta
- 2.01
- Short ratio
- 4.46
- Inst. own
- 84.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.01
- 200-d avg
- 2.02
- 1y target
- 3.02
5Y chart
Events in this range
- Aug 2, 2023Earnings: -0.26; estimate -0.34; surprise 23.53%
- Oct 30, 2023Earnings: -0.27; estimate -0.3; surprise 10%
- Feb 15, 2024Earnings: -0.27; estimate -0.31; surprise 12.9%
- May 9, 2024Earnings: -0.26; estimate -0.26; surprise 0%
- Aug 7, 2024Earnings: -0.2; estimate -0.24; surprise 16.67%
- Aug 12, 2024Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Aug 13, 2024Rating: Stephens & Co. · Overweight → Overweight
- Aug 28, 2024Rating: Scotiabank · Sector Outperform → Sector Outperform
- Nov 7, 2024Earnings: -0.17; estimate -0.2; surprise 15%
- Nov 11, 2024Rating: Piper Sandler · Neutral → Neutral
- Nov 11, 2024Rating: Scotiabank · Sector Outperform → Sector Outperform
- Nov 11, 2024Downgrade: UBS · Buy → Neutral
Signals (86)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 7, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| RSI: Overbought | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 18, 2025 | 1 year ago |
| SMA: Bearish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Oct 28, 2024 | 2 years ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 7, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 3, 2024 | 2 years ago |
| RSI: Oversold | Mar 4, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 15, 2024 | 2 years ago |
| SMA: Bearish | Jan 8, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 4, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 31, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 3, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bullish | Mar 20, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 27, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Dec 19, 2022 | 3 years ago |
| SMA: Bullish | Oct 17, 2022 | 4 years ago |
| SMA: Bullish | Oct 10, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
Key statistics
- Market cap
- 568.03M
- Enterprise value
- 989.12M
- Trailing P/E
- 0.00
- Forward P/E
- -2.84
- PEG ratio
- 0.00
- Price / sales
- 3.28
- Price / book
- 1.17
- EPS (TTM)
- -1.46
- Beta
- 2.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -227.69%
- Revenue (TTM)
- 173.15M
- Revenue growth
- -28.20%
- Free cash flow
- -190.76M
- Total cash
- 471.15M
- Total debt
- 920.75M
- Return on equity
- -64.80%
- Shares outstanding
- 294.32M
- Short % of float
- 21.05%
- 50-day average
- 2.01
- 200-day average
- 2.02
Analyst view
Consensus: buy
- Target (low)
- 2.00
- Target (mean)
- 3.02
- Target (high)
- 6.00
- Strong buy1
- Buy6
- Hold8
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.17551.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.20 | -0.17 | +0.03 | +15.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.24 | -0.20 | +0.04 | +16.67% |
| May 9, 2024 | Mar 1, 2024 | -0.26 | -0.26 | 0.00 | 0.00% |
| Feb 15, 2024 | Dec 1, 2023 | -0.31 | -0.27 | +0.04 | +12.90% |
| Oct 30, 2023 | Sep 1, 2023 | -0.30 | -0.27 | +0.03 | +10.00% |
| Aug 2, 2023 | Jun 1, 2023 | -0.34 | -0.26 | +0.08 | +23.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | UBS | down | Buy | Neutral |
| Nov 11, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Nov 11, 2024 | Piper Sandler | main | Neutral | Neutral |
| Aug 28, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Aug 13, 2024 | Stephens & Co. | main | Overweight | Overweight |
| Aug 12, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- pacb.com
News
- Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
- 10 Health Care Stocks Whale Activity In Today’s Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday
- PacBio to Participate in Upcoming Investor Conferences
- Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
- Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
- PacBio And Verily Health Announce Multi-Year Strategic Collaboration To Integrate PacBio HiFi Sequencing With Verily Health’s Governed Data And AI Platform
- PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
- Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Your note
Sign in to keep a note on PACB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| EIDEL JEFFREY | Officer | Sale | Aug 18, 2024 | 869,938 |
| ERICSON WILLIAM W | Director | Stock Award(Grant) | Jun 17, 2024 | 41,616 |
| HENRY CHRISTIAN O | Chief Executive Officer | Sale | Sep 15, 2024 | 2,497,760 |
| KIM SUSAN G | Chief Financial Officer | Sale | Sep 29, 2024 | 695,654 |
| LIVINGSTON RANDALL S | Director | Stock Award(Grant) | Jun 17, 2024 | 22,821 |
| MILLIGAN JOHN F | Director | Stock Award(Grant) | Jun 17, 2024 | 132,821 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 12.20% | 33,406,401 | 64.47M | Sep 29, 2024 |
| Madrone Advisors, LLC | 8.54% | 23,391,915 | 45.15M | Sep 29, 2024 |
| Blackrock Inc. | 8.49% | 23,252,682 | 44.88M | Sep 29, 2024 |
| Edmond De Rothschild Holding S.A. | 7.42% | 20,307,880 | 39.19M | Sep 29, 2024 |
| Vanguard Group Inc | 6.44% | 17,642,804 | 34.05M | Sep 29, 2024 |
| Sumitomo Mitsui Trust Holdings, Inc. | 4.33% | 11,865,766 | 22.90M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Innovation ETF | 6.91% | 18,937,397 | 36.55M | Oct 30, 2024 |
| ARK ETF Tr-ARK Genomic Revolution ETF | 4.52% | 12,389,944 | 23.91M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 3.26% | 8,930,679 | 17.24M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.57% | 7,047,500 | 13.60M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.45% | 3,984,497 | 7.69M | Sep 29, 2024 |
| Smallcap World Fund | 1.24% | 3,390,000 | 6.54M | Sep 29, 2024 |